Neovascular Age-Related Macular Degeneration

Ophthalmology
29
Pipeline Programs
17
Companies
50
Clinical Trials
7 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
2
5
0
9
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 28 programs with unclassified modality

On Market (3)

Approved therapies currently available

Roche
LUCENTISApproved
ranibizumab
Roche
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2006
Roche
SUSVIMOApproved
ranibizumab
Roche
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2021
Roche
VABYSMOApproved
faricimab
Roche
intravitreal2022

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
6 programs
1
2
2
1
Intravitreal Aflibercept Injection 2mgPhase 41 trial
Aflibercept High Dose VEGF Trap-EyePhase 3
Intravitreal Aflibercept Injection 2mgPhase 3
REGN2176-3Phase 22 trials
REGN910-3Phase 21 trial
+1 more programs
Active Trials
NCT01997164Completed20Est. Oct 2015
NCT02418754Terminated505Est. Apr 2017
NCT02061865Completed12Est. Dec 2014
+2 more trials
Bayer
BayerLEVERKUSEN, Germany
4 programs
1
1
aflibercept 2mgPhase 41 trial
Intravitreal Aflibercept Injection 2mgPhase 31 trial
AfliberceptN/A1 trial
anti-VEGF treatmentN/A1 trial
Active Trials
NCT04641234Completed330Est. Jun 2021
NCT06495203Completed1,350Est. Feb 2024
NCT00964795Completed323Est. Aug 2013
+1 more trials
Roche
RocheSTAVANGER NORWAY, Norway
4 programs
4
1
VABYSMO(Faricimab)Phase 3Monoclonal Antibody5 trials
PDS Implant filled with 100 mg/mL RanibizumabPhase 3Monoclonal Antibody1 trial
PDS With RanibizumabPhase 3Monoclonal Antibody1 trial
RanibizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06795048Active Not Recruiting274Est. Sep 2027
NCT06176352Active Not Recruiting280Est. May 2026
NCT05610319Active Not Recruiting446Est. Dec 2026
+5 more trials
Novartis
NovartisBASEL, Switzerland
2 programs
1
RanibizumabPhase 4Monoclonal Antibody1 trial
nAMDN/A1 trial
Active Trials
NCT04935411Terminated2,665Est. Dec 2022
NCT01775124Completed332Est. Nov 2015
Genentech
GenentechCA - Oceanside
1 program
1
PDS Implant With Ranibizumab 100 mg/mlPhase 41 trial
Active Trials
NCT04853251Recruiting188Est. Apr 2028
Alcon
AlconFORT WORTH, TX
2 programs
1
1
Brolucizumab ophthalmic solutionPhase 31 trial
Brolucizumab 3 mg/50 μLPhase 21 trial
Active Trials
NCT02507388Completed51Est. Sep 2016
NCT02307682CompletedEst. Mar 2018
Outlook Therapeutics
1 program
1
bevacizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT06190093CompletedEst. Dec 2024
Astellas
AstellasChina - Shenyang
1 program
1
Avacincaptad PegolPhase 25 trials
Active Trials
NCT06970665Recruiting20Est. Jun 2027
NCT06779773Recruiting1,000Est. Jan 2030
NCT05536297Completed278Est. Apr 2025
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
RGX-314Phase 25 trials
Active Trials
NCT07007065Recruiting561Est. Mar 2033
NCT05296447Enrolling By Invitation100Est. May 2028
NCT05407636Recruiting660Est. Nov 2027
+2 more trials
Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
2 programs
1
1
PegcetacoplanPhase 1/21 trial
PegcetacoplanPhase 11 trial
Active Trials
NCT02461771Completed13Est. Mar 2016
NCT03465709Terminated17Est. Apr 2019
Sanofi
SanofiPARIS, France
1 program
1
SAR402663Phase 1/21 trial
Active Trials
NCT06660667Recruiting66Est. Jun 2031
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
2
TK001Phase 11 trial
TK001Phase 11 trial
Active Trials
NCT02613559UnknownEst. Sep 2018
NCT03021785UnknownEst. Nov 2018
AffaMed Therapeutics
AffaMed TherapeuticsChina - Beijing
1 program
1
AM712Phase 11 trial
Active Trials
NCT05345769CompletedEst. Nov 2024
DS
Daiichi SankyoChina - Shanghai
1 program
1
DS-7080aPhase 11 trial
Active Trials
NCT02530918Completed56Est. Jan 2018
NV
Notal VisionVA - Manassas
3 programs
Home OCT Fluid Visualization Agreement StudyN/A1 trial
Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification StudyN/A1 trial
Single In-Clinic Encounter With the Notal Vision Home OCTN/A1 trial
Active Trials
NCT04907409UnknownEst. Aug 2022
NCT05281042CompletedEst. Jan 2022
NCT04642183CompletedEst. Sep 2021
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
AfliberceptN/A1 trial
Active Trials
NCT02457026Withdrawn0Est. Jan 2018
Pfizer
PfizerNEW YORK, NY
1 program
MacugenN/A1 trial
Active Trials
NCT00820742Withdrawn0Est. May 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstellasAvacincaptad Pegol
RocheFaricimab
RocheFaricimab
GenentechPDS Implant With Ranibizumab 100 mg/ml
RegeneronIntravitreal Aflibercept Injection 2mg
Bayeraflibercept 2mg
NovartisRanibizumab
AbbVieRGX-314
RochePDS With Ranibizumab
RocheFaricimab
Outlook Therapeuticsbevacizumab
RocheRanibizumab
AstellasAvacincaptad Pegol
AbbVieRGX-314
RocheFaricimab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 15,386 patients across 50 trials

NCT06970665AstellasAvacincaptad Pegol

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Start: Jul 2025Est. completion: Jun 202720 patients
Phase 4Recruiting
NCT06795048RocheFaricimab

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Start: Mar 2025Est. completion: Sep 2027274 patients
Phase 4Active Not Recruiting
NCT05610319RocheFaricimab

Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Start: May 2023Est. completion: Dec 2026446 patients
Phase 4Active Not Recruiting
NCT04853251GenentechPDS Implant With Ranibizumab 100 mg/ml

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Start: Dec 2021Est. completion: Apr 2028188 patients
Phase 4Recruiting
NCT03468296RegeneronIntravitreal Aflibercept Injection 2mg

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

Start: Apr 2018Est. completion: Jul 201922 patients
Phase 4Unknown
NCT02309281Bayeraflibercept 2mg

Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab

Start: May 2013Est. completion: Jul 201433 patients
Phase 4Completed
NCT01775124NovartisRanibizumab

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Start: Feb 2013Est. completion: Nov 2015332 patients
Phase 4Completed
NCT07007065AbbVieRGX-314

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Start: Nov 2025Est. completion: Mar 2033561 patients
Phase 3Recruiting
NCT05562947RochePDS With Ranibizumab

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Start: Jun 2024Est. completion: Aug 202968 patients
Phase 3Recruiting
NCT06176352RocheFaricimab

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Start: Mar 2024Est. completion: May 2026280 patients
Phase 3Active Not Recruiting
NCT06190093Outlook Therapeuticsbevacizumab

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

Start: Jan 2024Est. completion: Dec 2024
Phase 3Completed
NCT05126966RocheRanibizumab

A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

Start: Dec 2023Est. completion: Jan 20260
Phase 3Withdrawn
NCT05536297AstellasAvacincaptad Pegol

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Start: Sep 2022Est. completion: Apr 2025278 patients
Phase 3Completed
NCT05407636AbbVieRGX-314

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Start: Jan 2022Est. completion: Nov 2027660 patients
Phase 3Recruiting
NCT04777201RocheFaricimab

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Start: Apr 2021Est. completion: Sep 20241,036 patients
Phase 3Completed
NCT03823300RocheFaricimab

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Start: Mar 2019Est. completion: Jan 2022658 patients
Phase 3Completed
NCT03823287RocheFaricimab

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Start: Feb 2019Est. completion: Jan 2022671 patients
Phase 3Completed
NCT03622593RocheFaricimab

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

Start: Oct 2018Est. completion: May 2023951 patients
Phase 3Completed
NCT03677934RochePDS Implant filled with 100 mg/mL Ranibizumab

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

Start: Sep 2018Est. completion: Jun 2021415 patients
Phase 3Completed
NCT02307682AlconBrolucizumab ophthalmic solution

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

Start: Dec 2014Est. completion: Mar 2018
Phase 3Completed
NCT00964795BayerIntravitreal Aflibercept Injection 2mg

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Start: Dec 2009Est. completion: Aug 2013323 patients
Phase 3Completed
NCT04832724AbbVieRGX-314

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Start: Feb 2021Est. completion: Mar 202460 patients
Phase 2Completed
NCT04597918RocheFaricimab

A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab

Start: Nov 2020Est. completion: Dec 202299 patients
Phase 2Completed
NCT04567550AbbVieRGX-314

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

Start: Nov 2020Est. completion: Dec 2026139 patients
Phase 2Active Not Recruiting
NCT03999801AbbVieRGX-314

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Start: May 2019Est. completion: Dec 2028865 patients
Phase 2Enrolling By Invitation
NCT03038880RocheFaricimab

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Start: Jan 2017Est. completion: Mar 201876 patients
Phase 2Completed
NCT05571267AstellasAvacincaptad Pegol

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Start: Oct 2016Est. completion: Apr 20181 patients
Phase 2Terminated
NCT02713204RegeneronREGN910-3

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Start: Mar 2016Est. completion: Oct 2017365 patients
Phase 2Completed
NCT02507388AlconBrolucizumab 3 mg/50 μL

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

Start: Aug 2015Est. completion: Sep 201651 patients
Phase 2Completed
NCT02484690RocheFaricimab

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Start: Aug 2015Est. completion: Sep 2017273 patients
Phase 2Completed
NCT02418754RegeneronREGN2176-3

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

Start: May 2015Est. completion: Apr 2017505 patients
Phase 2Terminated
NCT06660667SanofiSAR402663

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Start: Nov 2024Est. completion: Jun 203166 patients
Phase 1/2Recruiting
NCT03465709Apellis PharmaceuticalsPegcetacoplan

Pegcetacoplan (APL-2) in Neovascular AMD

Start: Feb 2018Est. completion: Apr 201917 patients
Phase 1/2Terminated
NCT05345769AffaMed TherapeuticsAM712

Safety and Efficacy of AM712 in Patients with NAMD

Start: Apr 2022Est. completion: Nov 2024
Phase 1Completed
NCT03021785T-TherapeuticsTK001

A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration

Start: Oct 2017Est. completion: Nov 2018
Phase 1Unknown
NCT02613559T-TherapeuticsTK001

Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

Start: Nov 2015Est. completion: Sep 2018
Phase 1Unknown
NCT02530918Daiichi SankyoDS-7080a

Study of DS-7080a for the Treatment of Macular Degeneration

Start: Jul 2015Est. completion: Jan 201856 patients
Phase 1Completed
NCT02461771Apellis PharmaceuticalsPegcetacoplan

Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD

Start: Jan 2015Est. completion: Mar 201613 patients
Phase 1Completed
NCT01997164RegeneronREGN910-3

Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)

Start: Nov 2014Est. completion: Oct 201520 patients
Phase 1Completed
NCT02061865RegeneronREGN2176-3

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Start: Feb 2014Est. completion: Dec 201412 patients
Phase 1Completed
NCT00950638AstellasAvacincaptad Pegol

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Start: Jul 2009Est. completion: Mar 201147 patients
Phase 1Completed
NCT00709527AstellasAvacincaptad Pegol

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

Start: Oct 2008Est. completion: Dec 200960 patients
Phase 1Completed
NCT06779773AstellasAvacincaptad Pegol

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Start: Jan 2025Est. completion: Jan 20301,000 patients
N/ARecruiting
NCT06495203Bayeranti-VEGF treatment

A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO

Start: Nov 2023Est. completion: Feb 20241,350 patients
N/ACompleted
NCT05296447AbbVieRGX-314

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy

Start: Apr 2022Est. completion: May 2028100 patients
N/AEnrolling By Invitation
NCT05281042Notal VisionHome OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study

Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study

Start: Sep 2021Est. completion: Jan 2022
N/ACompleted
NCT04907409Notal VisionHome OCT Fluid Visualization Agreement Study

Home OCT Fluid Visualization Agreement Study

Start: Jun 2021Est. completion: Aug 2022
N/AUnknown
NCT04935411NovartisnAMD

Russian Registry of Patients With nAMD

Start: Dec 2020Est. completion: Dec 20222,665 patients
N/ATerminated
NCT04641234BayerAflibercept

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).

Start: Dec 2020Est. completion: Jun 2021330 patients
N/ACompleted
NCT04642183Notal VisionSingle In-Clinic Encounter With the Notal Vision Home OCT

Single In-Clinic Encounter With the Notal Vision Home OCT

Start: Nov 2020Est. completion: Sep 2021
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 15,386 patients
17 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Macular Degeneration(37)Diabetic Retinopathy(25)Cataracts(22)